FGF2 and paraplegia: In the present study, dMSCs and SKPs were isolated simultaneously from the same back skin sample from patients with paraplegia when SKP proliferation medium (DMEM/F12 containing 40 ng/ml FGF2 and 20 ng/ml EGF) was used during the initial stage.